N W C J van de Donk
Overview
Explore the profile of N W C J van de Donk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Musto P, Engelhardt M, van de Donk N, Gay F, Terpos E, Einsele H, et al.
Ann Oncol
. 2025 Feb;
PMID: 39924085
Background: Primary plasma cell leukemia (PPCL) is the most aggressive disorder among plasma cell malignancies, with new diagnostic criteria recently established by the International Myeloma Working Group. Studies have shown...
2.
Seefat M, Stege C, Lissenberg-Witte B, Levin M, Timmers G, Hoogendoorn M, et al.
Eur J Cancer
. 2024 Jun;
207:114153.
PMID: 38870747
Background: Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality of life (HRQoL). Currently, data on changes in HRQoL of frail and...
3.
Laheij A, van de Donk N
Support Care Cancer
. 2023 Dec;
32(1):20.
PMID: 38092979
Purpose: In recent years, various immunotherapies have improved the survival of patients with multiple myeloma (MM). However, there remains an unmet need for novel agents. Talquetamab is the first-in-class GPRC5D-targeting...
4.
Seefat M, Cucchi D, Groen K, Donker M, van der Hem K, Westerman M, et al.
Eur J Haematol
. 2023 Oct;
112(3):360-366.
PMID: 37821211
Novel therapies for multiple myeloma (MM) have improved patient survival, but their high costs strain healthcare budgets. End-of-life phases of treatment are generally the most expensive, however, these high costs...
5.
Amaador K, Peeters H, Minnema M, Nguyen T, Dendooven A, Vos J, et al.
Neth J Med
. 2019 Oct;
77(7):243-254.
PMID: 31582582
Monoclonal gammopathy of renal significance (MGRS) includes all kidney disorders caused by a monoclonal protein (M-protein) secreted by a small plasma cell clone or other B-cell clones in patients who...
6.
Wagemakers A, Visser M, de Wever B, Hovius J, van de Donk N, Hendriks E, et al.
BMC Infect Dis
. 2018 Aug;
18(1):362.
PMID: 30071836
Background: Infection with Borrelia burgdorferi sensu lato complex (B. b. sl) spirochetes can cause Lyme borreliosis, manifesting as localized infection (e.g. erythema migrans) or disseminated disease (e.g. Lyme neuroborreliosis). Generally,...
7.
Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, et al.
Leukemia
. 2017 Dec;
PMID: 29251284
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment outcome. All of these novel substances differ...
8.
Kumar S, Dimopoulos M, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al.
Leukemia
. 2017 Jun;
31(11):2443-2448.
PMID: 28620163
Introduction of new myeloma therapies offers new options for patients refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients with relapsed multiple myeloma, who have...
9.
Franken B, van de Donk N, Cloos J, Zweegman S, Lokhorst H
Ther Adv Hematol
. 2016 Dec;
7(6):330-344.
PMID: 27904737
Even though the prognosis of patients with multiple myeloma is continuing to improve, all patients eventually develop relapsed refractory disease. Several novel therapeutics have been developed in the last few...
10.
van de Donk N, Mutis T, Poddighe P, Lokhorst H, Zweegman S
Int J Lab Hematol
. 2016 May;
38 Suppl 1:110-22.
PMID: 27161311
Monoclonal gammopathy of undetermined significance (MGUS) is one of the most common premalignant disorders. IgG and IgA MGUS are precursor conditions of multiple myeloma (MM), whereas light-chain MGUS is a...